The Art of
Licensing
About Helsinn
• Board of Directors and Top Management
• Contacts
• News
2009
2010
2011
2012
2013
Our locations
• Switzerland
• Ireland
• USA
Helsinn's recent history
The Art of
Development
Building pharmaceuticals
Our R&D
The Art of
Access
Making pharmaceuticals available
Our products
• Cancer Supportive Care
Palonosetron
Gelclair
Netupitant
Anamorelin
Elsiglutide ZP1846
DaxibeQOL
• Pain and Inflammation
Nimesulide
Oxaprozin
• Gastroenterology
Palonosetron
Klean-Prep
Ipamorelin
• Areas under development
The Ghrelin Family
The Art of
Manufacturing
High standard technologies
Helsinn Advanced Synthesis SA, Biasca
Helsinn Birex Pharmaceuticals Ltd, Dublin
The Art of
Partnership
Shaping alliances
• Our partners
Home
>
The Art of Access
>
Our products
>
Cancer Supportive Care
>
Netupitant
Netupitant
Netupitant is a potent and selective NK
1
receptor antagonist. It is under development in combination with palonosetron for the prevention of chemotherapy-induced-nausea and vomiting (CINV).
Development status: Phase 3
Copyright © Helsinn Group - Legal Statement
Last Update: 21.05.2013
Free acces to Helsinn newsletter
Subscribe
or
Unsubscribe
About Helsinn
Our Products
Our Partners